RESUMO
Vulvovaginal atrophy (VVA) is a chronic and progressive disease that affects sexuality and quality of life. VVA is preventable and treatable, but requires long-term and often sequential treatment. Sequential treatment consists of designing a strategy that uses one or more medications for a long enough time to achieve the desired benefits with minimal risk and maximum adherence. Currently available therapeutic options consist of topical over-the-counter products (including non-hormonal lubricants and moisturizers applied to the vagina), systemic hormone therapy and estrogens, and prescribed vaginal dehydroepiandrosterone (DHEA). In addition, we have a selective estrogen receptor modulator, ospemifene, and new energy-based treatments (laser and radiofrequency). There are clear differences between the treatments both in the mechanism of action and in the efficacy. Compliance is very low, and patients complain about the use of the vaginal route, often due to its low efficacy, or express fear of the long-term use of estrogens or the price of the treatments. We believe that, as a first option, and for physiological, preventive and efficacy reasons, we should consider the prescription of treatments that work on estrogen receptors. As a second option, there are vaginal moisturizers, which are effective on symptoms but do not prevent or improve conditions. Finally, techniques using heat, which although each time represent a clearer alternative, but on the other hand are the cost and the long-term safety data, give us a third option. Of course, we consider that vulvar moisturizers and lubricants can be used at any time.
Assuntos
Dispareunia , Pós-Menopausa , Feminino , Humanos , Qualidade de Vida , Estrogênios/uso terapêutico , Moduladores Seletivos de Receptor Estrogênico/uso terapêutico , Vagina/patologia , Vulva/patologia , Atrofia/tratamento farmacológico , Lubrificantes/uso terapêutico , Dispareunia/tratamento farmacológicoRESUMO
To describe the experience in a recently created ocular graft-versus-host disease unit in a tertiary hospital and to detail ocular surface features and complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This retrospective study included all patients who underwent allo-HSCT, with or without chronic GVHD and were being monitored in the Hematopoietic Stem Cell Transplantation Unit in the UNICAMP Clinical Hospital (Campinas, Sao Paulo, Brazil) from 2015 to 2020. Patients were concomitantly evaluated by hematology and ophthalmology teams of the Ocular GVHD Unit. Hematologists performed a comprehensive systemic evaluation searching and grading mouth, skin, lungs, gastrointestinal tract, liver and genitalia GVHD. While ophthalmologists evaluated ocular symptoms through specific questionnaire (Ocular Surface Disease Index-OSDI) and a protocol of distinct ocular surface parameters for dry eye disease (1) and ocular complications, which encompassed meniscometry, non-invasive tear break-up time (NITBUT) measurement, conjunctival hyperemia quantification, meibography, fluorescein and lissamine staining and Schirmer's test. Patients were diagnosed with chronic GVHD using the National Institutes of Health (NIH) Consensus Criteria for Chronic Graft-versus-Host Disease. The International Chronic Ocular GVHD Consensus Group (ICOGCG) score was obtained at the onset of ocular disease presentation or afterwards. A total of 82 patients underwent allo-HSCT (97.6% full matched and 2.4% haploidentical), mainly for cases of leukemia and 73.2% had chronic GVHD. Mean onset time for chronic GVHD was 232 ± 7.75 days. The mouth, skin, and eyes were the main organs involved (63%, 50%, and 48%, respectively). Symptom scores and all ocular surface parameters differ in patients with and without chronic GVHD and along different timepoints of the follow-up. Ocular complications mostly involved were severe DED and meibomian gland dysfunction, conjunctival scarring, cataract and infections resulting in keratitis and corneal perforation. As therapeutic strategies, 73% patients received preservative-free lubricants, 27% autologous serum, 48% topical steroids, 27% oral tetracycline derivatives, 22% mucolytic eye drops and 3 patients needed bandage contact lens. Ocular GVHD is a complex and challenging disease with varied manifestations, resulting in a broad range of ocular test endpoints, and inconsistent treatment responses. The main ocular presentations were dry eye, meibomian gland dysfunction and cataracts. The therapeutic approach often involves topical steroids and autologous serum tears. It is important to monitor these patients closely, so the ocular GVHD Unit may improve the care, providing prompt identification of ocular manifestations and faster treatment of complications.
Assuntos
Síndromes do Olho Seco , Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Disfunção da Glândula Tarsal , Brasil , Síndromes do Olho Seco/diagnóstico , Síndromes do Olho Seco/etiologia , Síndromes do Olho Seco/terapia , Expectorantes/uso terapêutico , Fluoresceína/metabolismo , Doença Enxerto-Hospedeiro/diagnóstico , Doença Enxerto-Hospedeiro/tratamento farmacológico , Doença Enxerto-Hospedeiro/etiologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Lubrificantes/uso terapêutico , Soluções Oftálmicas/uso terapêutico , Estudos Retrospectivos , Tetraciclinas/uso terapêutico , Transtornos da Visão/complicaçõesRESUMO
Genitourinary syndrome of menopause (GSM) is the term used to describe the group of symptoms including vaginal pain, vaginal dryness, itching, pain during sexual intercourse and fragile vaginal tissues as well as urinary symptoms including urinary frequency, urgency, incontinence, blood in the urine (haematuria) and recurrent urinary tract infections that occur due to a lack of the hormone estrogen. These symptoms can have a significant negative impact on psychosexual issues, sexual function and quality of life in postmenopausal women. Traditionally women have been treated with vaginal lubricants, vaginal moisturisers or low-dose vaginal estrogens. Lasers have been used in the cosmetic industry for collagen remodelling and repair of the skin. Therefore, it has been suggested that laser therapy may be used on the vagina as an alternative treatment for GSM. A review of all the published studies assessing the safety and efficacy of laser therapy for GSM have shown promising beneficial results. The majority of studies to date have been small, short-term, observational studies. However, there are randomised controlled trials underway. Laser treatment may be beneficial for the symptoms of GSM but until more robust evidence is available it should not be adopted into widespread practice, and should be used as part of a research study only.
Assuntos
Terapia a Laser , Doenças Vaginais , Estrogênios , Feminino , Humanos , Terapia a Laser/efeitos adversos , Terapia a Laser/métodos , Lubrificantes/uso terapêutico , Menopausa , Dor , Qualidade de Vida , Síndrome , Vagina/cirurgia , Doenças Vaginais/cirurgiaRESUMO
PURPOSE: To determine the prevalence of adenoviral conjunctivitis in Turkish ophthalmologists, to provide an overview of the treatment and prophylaxis of adenoviral conjunctivitis, and to analyze the data in the context of evidence-based treatment recommendations. METHODS: An online questionnaire consisting of 20 multiple-choice questions about the characteristics of the respondents, the individual adenoviral conjunctivitis history of the ophthalmologists, their practice's approaches, and prescription preferences were emailed to Turkish ophthalmologists. RESULTS: The survey was emailed to 500 ophthalmologists; 45% of them returned the questionnaire. According to the responses, the history of adenoviral conjunctivitis infections was positive in 46.7% (n: 120), recurrent attack prevalence was 16.2% in ophthalmologists. Lubricants (67.6%) are the most preferred first-line treatment options for adenoviral conjunctivitis, followed by povidone-iodine (59.6%), topical antibiotics (51.1%), topical antivirals (29.3%), topical corticosteroids (26.7%), and topical nonsteroidal anti-inflammatory agents (19.6%). A total of 98.2% preferred to dismiss infected patients. The preferred prophylaxis options were frequent hand washing/use of gloves (97.8%), disinfection of medical devices (95.1%), isolation of infected patients (79.1%), hand hygiene with gemicides (58.7%). The percentage of single-dose eye drop selection was 46.2. CONCLUSIONS: The findings of this survey showed that most Turkish ophthalmologists generally follow international guidelines for the treatment of adenoviral conjunctivitis. The treatment algorithm is still controversial, so ophthalmologists should be aware of treatment guideline updates in line with evidence-based recommendations. Having sufficient knowledge of the basic characteristics of viruses is important to control the spread of the disease.
Assuntos
Infecções por Adenoviridae , Conjuntivite Viral , Conjuntivite , Oftalmologistas , Infecções por Adenoviridae/tratamento farmacológico , Corticosteroides/uso terapêutico , Antibacterianos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Antivirais/uso terapêutico , Conjuntivite/tratamento farmacológico , Conjuntivite Viral/tratamento farmacológico , Conjuntivite Viral/epidemiologia , Conjuntivite Viral/prevenção & controle , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Lubrificantes/uso terapêutico , Soluções Oftálmicas/uso terapêutico , Povidona-Iodo/uso terapêutico , Inquéritos e QuestionáriosRESUMO
Genitourinary syndrome of menopause (GSM) is a term that describes the genital, urinary, and sexual changes that occur in women because of a lack of estrogen. This most commonly is because of menopause, but can be because of a hypoestrogenic state caused by hyperprolactinemia, oophorectomy, premature ovarian failure, chemotherapy, or radiation. GSM describes a group of signs and symptoms that affect quality of life and progress over time, including vaginal dryness, dyspareunia, dysuria, urinary urgency, and frequent urinary tract infections. GSM is underdiagnosed. It affects 65% of women 1 year after the onset of menopause, and 84% of women 6 years after menopause. Physicians routinely should ask all perimenopausal and postmenopausal women about GSM symptoms. The diagnosis is made clinically, based on the history and physical examination. Use of nonhormonal lubricants and vaginal moisturizers should be recommended as first-line therapies. Vaginal estrogen is the most effective treatment. Other therapies include vaginal dehydroepiandrosterone (DHEA), ospemifene, systemic estrogen therapy, and pelvic floor physical therapy.
Assuntos
Menopausa , Qualidade de Vida , Estrogênios/uso terapêutico , Feminino , Humanos , Lubrificantes/uso terapêutico , SíndromeRESUMO
PURPOSE: Side-effects of adjuvant endocrine therapy (AET) are common in breast cancer survivors, and can affect adherence to treatment. We synthesised the evidence for strategies to self-manage these side-effects. METHODS: We searched for systematic reviews and clinical guidelines on self-management strategies for AET side-effects (arthralgia, fatigue, hot flashes, gastrointestinal discomfort, nausea, vulvovaginal symptoms, and sleep disturbance). We searched oncology organisation's websites and eight databases (Inception-November 2020). Screening, data extraction and quality assessment were completed independently in duplicate. PROSPERO: 2019CRD4201914001. RESULTS: We identified 33 systematic reviews and 18 clinical guidelines. 21% of reviews were high quality, and the average quality score for guidelines was 44%. Evidence for most strategies was absent or weak. There was consensus from a low-quality review and multiple guidelines to recommend moisturisers, gels and lubricants for vulvovaginal symptoms. Evidence was weak for physical activity for self-managing most symptoms, although two high-quality reviews indicated yoga and aerobic exercise could reduce fatigue. Primary research was often biased by weak and underpowered study designs. Eleven reviews did not report information on adverse events. CONCLUSIONS: Most self-management strategies for breast cancer survivors experiencing side-effects from AET lack evidence. Primary research is needed using high-quality well-powered designs focusing on implementable strategies. IMPLICATIONS FOR CANCER SURVIVORS: Patients and clinicians should be aware that although the risk of harm is low for these self-management strategies, the likelihood of benefit is often unclear. Women should consider moisturisers, gels or lubricants for self-managing vulvovaginal symptoms, and yoga or aerobic exercise for alleviating fatigue.
Assuntos
Neoplasias da Mama , Sobreviventes de Câncer , Autogestão , Humanos , Feminino , Neoplasias da Mama/tratamento farmacológico , beta-Aminoetil Isotioureia/uso terapêutico , Revisões Sistemáticas como Assunto , Fadiga/induzido quimicamente , Fadiga/terapia , Lubrificantes/uso terapêuticoRESUMO
Entender el desgaste prematuro en reemplazos articulares debido a una lubricación deficiente, que puede resultar en valores de fricción altos, es un tema amplio e intrincado de abordar. Además, si el lubricante es el fluido sinovial, los mecanismos de lubricación que ocurren son aún más complejos de develar. En este artículo se revisa el estado de conocimiento actual de la lubricación sinovial, así como las características reológicas del fluido lubricante. Asimismo, se mencionan algunas técnicas experimentales y métodos numéricos con los que se ha estudiado el problema de la lubricación. En algunas simulaciones numéricas de la lubricación en reemplazos articulares no se considera el efecto del esfuerzo cortante del líquido sinovial ya que se asume que tiene un comportamiento newtoniano, sin embargo, otras investigaciones han demostrado que al asumir un comportamiento no newtoniano el proceso de lubricación se afecta significativamente. Con todo esto, incorporar todos los factores que pueden afectar la lubricación en reemplazos articulares, en simulaciones numéricas hasta la fecha es un reto. A través de diversas investigaciones se buscan nuevos materiales, diseños y técnicas de análisis que permitan incrementar la vida útil de los implantes para así reducir las cirugías de revisión(AU)
derstanding premature wear in joint replacements due to poor lubrication, which can result in high friction values, is a broad and intricate topic to address. In addition, if the lubricant is the synovial fluid, the lubrication mechanisms that occur are even more complex to unveil. This article reviews the current state of knowledge on synovial lubrication, as well as the rheological characteristics of the lubricating fluid. It is also made a mention of some experimental techniques and numerical methods with which the problem of lubrication has been studied. In some numerical simulations of lubrication in joint replacements the effect of the shear stress of the synovial fluid is not considered since it is assumed to have a Newtonian behavior; however, other research has shown that by assuming a non-Newtonian behavior the lubrication process is significantly affected. With all this, incorporating all the factors that can affect lubrication in joint replacements, in numerical simulations to date is a challenge. Through various investigations, new materials, designs and analysis techniques are sought to increase the useful life of implants in order to reduce revision surgeries(AU)
Assuntos
Humanos , Técnicas In Vitro/métodos , Lubrificantes/uso terapêutico , Prótese Articular , Artroplastia/métodosRESUMO
The purpose of this study is to apply a machine learning approach to predict whether patients with burning mouth syndrome (BMS) respond to the initial approach and clonazepam therapy based on clinical data. Among the patients with the primary type of BMS who visited the clinic from 2006 to 2015, those treated with the initial approach of detailed explanation regarding home care instruction and use of oral topical lubricants, or who were prescribed clonazepam for a minimum of 1 month were included in this study. The clinical data and treatment outcomes were collected from medical records. Extreme Gradient-Boosted Decision Trees was used for machine learning algorithms to construct prediction models. Accuracy of the prediction models was evaluated and feature importance calculated. The accuracy of the prediction models for the initial approach and clonazepam therapy was 67.6% and 67.4%, respectively. Aggravating factors and psychological distress were important features in the prediction model for the initial approach, and intensity of symptoms before administration was the important feature in the prediction model for clonazepam therapy. In conclusion, the analysis of treatment outcomes in patients with BMS using a machine learning approach showed meaningful results of clinical applicability.
Assuntos
Síndrome da Ardência Bucal/terapia , Clonazepam/uso terapêutico , Aprendizado de Máquina , Prognóstico , Síndrome da Ardência Bucal/diagnóstico , Síndrome da Ardência Bucal/patologia , Clonazepam/efeitos adversos , Feminino , Humanos , Lubrificantes/efeitos adversos , Lubrificantes/uso terapêutico , Masculino , Pessoa de Meia-Idade , Mucosite/tratamento farmacológico , Mucosite/patologia , Resultado do TratamentoRESUMO
AbstractPromoting sexual health is a World Health Organization (WHO) priority. Lubricants are widely available and used to improve sexual pleasure and reduce pain during intercourse. To inform WHO's self-care interventions guideline, we conducted a systematic review of the peer-reviewed literature to answer the question: does use of lubricants during or prior to sex result in improved sexual health and well-being. We searched PubMed, CINAHL, LILACS and EMBASE on 8 July 2020 for effectiveness, values and preferences, and cost data related to commercially available vaginal and anal lubricants. Data were systematically extracted and qualitatively synthesised. Effectiveness evidence was summarised in GRADE evidence profiles. Seven studies met the effectiveness review criteria. Two randomised trials found lubricant use led to improved female sexual well-being and had no impact on incidence of human papillomavirus (moderate certainty evidence). One observational study with gay and bisexual men showed lubricants were associated with increased reports of pain during receptive intercourse and no difference in pain during insertive intercourse, but a reduced degree of pain in both types of intercourse (low/very low certainty evidence). One observational study with female breast cancer survivors found better outcomes of vaginal dryness and dyspareunia with lubricant use (very low certainty evidence). Twenty-one values and preferences studies from diverse populations globally found that most individuals supported lubricant use for reasons of comfort/reduced pain and sexual pleasure. No cost studies were identified. Although evidence is limited, lubricants appear to offer an acceptable approach to improving sexual health and well-being.
Assuntos
Lubrificantes , Saúde Sexual , Bissexualidade , Coito , Feminino , Humanos , Lubrificantes/uso terapêutico , Masculino , Estudos Observacionais como Assunto , Comportamento SexualRESUMO
Ocular complications in critical care patients are common. There has been a surge in intensive care admissions following the COVID-19 outbreak. The management of COVID-19 exposes patients to a number of specific risk factors for developing ocular complications, which include non-invasive ventilation, mechanical ventilation and prone positioning. Consequently, it is likely that there will be an increase in the number of ocular complications secondary to the management of COVID-19 patients in the intensive care unit setting, and these complications could lead to permanent visual loss and blindness. Increased awareness of eye care in the intensive care unit setting is therefore vital to help prevent visual loss and maintain quality of life for patients recovering from COVID-19.
Assuntos
Infecções por Coronavirus/terapia , Oftalmopatias/terapia , Unidades de Terapia Intensiva , Oftalmologia , Pneumonia Viral/terapia , Encaminhamento e Consulta , Doença Aguda , Betacoronavirus , COVID-19 , Doenças da Túnica Conjuntiva/prevenção & controle , Doenças da Túnica Conjuntiva/terapia , Conjuntivite/prevenção & controle , Conjuntivite/terapia , Doenças da Córnea/prevenção & controle , Doenças da Córnea/terapia , Lesões da Córnea/prevenção & controle , Lesões da Córnea/terapia , Cuidados Críticos , Estado Terminal , Edema/prevenção & controle , Edema/terapia , Endoftalmite/prevenção & controle , Endoftalmite/terapia , Oftalmopatias/prevenção & controle , Glaucoma/diagnóstico , Glaucoma/terapia , Humanos , Ceratite/prevenção & controle , Ceratite/terapia , Lubrificantes/uso terapêutico , Pomadas/uso terapêutico , Pandemias , SARS-CoV-2 , Transtornos da Visão/diagnóstico , Transtornos da Visão/terapiaRESUMO
Osteoarthritis, which is characterized by irreversible destruction of articular cartilage and severe inflammation of joint capsule, may be effectively treated via the synergistic therapy of lubrication restoration and local drug intervention. In this study, zwitterionic polymer-grafted mesoporous silica nanoparticles (MSNs@pSBMA) with the property of enhanced lubrication and sustained drug release were successfully synthesized via photopolymerization of 3-[dimethyl-[2-(2-methylprop-2-enoyloxy) ethyl] azaniumyl] propane-1-sulfonate polymer (pSBMA) on the surface of MSNs. The tribiological test showed that the lubrication performance of MSNs@pSBMA was remarkably improved, with a reduction of 80% in friction coefficient compared with MSNs. It was attributed to hydration lubrication mechanism by which a tenacious hydration layer was formed surrounding the N+(CH2)2(CH3)2 and SO3- headgroups in the pSBMA polyelectrolyte polymer. Additionally, the surface morphology analysis of the tribopairs demonstrated that MSNs@pSBMA were endowed with excellent anti-wear performance. Importantly, the drug release test illustrated that, compared with MSNs, MSNs@pSBMA achieved good sustained drug release behavior. In summary, the MSNs@pSBMA nanoparticles developed herein, as an injectable lubricant with enhanced lubrication and drug delivery, may represent a promising approach for the treatment of osteoarthritis.
Assuntos
Betaína/análogos & derivados , Portadores de Fármacos/química , Lubrificantes/química , Nanopartículas/química , Polímeros/química , Dióxido de Silício/química , Betaína/química , Liberação Controlada de Fármacos , Humanos , Lubrificantes/uso terapêutico , Osteoartrite/tratamento farmacológico , Osteoartrite/patologia , Polímeros/síntese química , Porosidade , Rodaminas/química , Rodaminas/metabolismo , Propriedades de SuperfícieRESUMO
INTRODUCTION: Gay, bisexual and other men who have sex with men (gbMSM) have an increased risk of human papillomavirus (HPV) infection and HPV-associated diseases, such as anal cancer and anogenital warts. A carrageenan-based lubricant could prevent HPV infection, thereby reducing the disease burden in this population. This paper describes the protocol for the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) study, an ongoing randomised controlled trial (RCT), evaluating efficacy of a carrageenan-based personal lubricant in reducing type-specific anal HPV incidence and prevalence among sexually active gbMSM, efficacy by HIV status, safety and tolerability of the gel and participant adherence to the intervention. METHODS AND ANALYSIS: The study is a double-blinded, placebo-controlled RCT. Volunteer gbMSM 18 years and older are randomly assigned 1:1 to receive the treatment (a self-applied anal microbicide gel with carrageenan) or placebo (a self-applied placebo gel). At each visit, computerised questionnaires are used to collect data on sociodemographic and clinical variables, lifestyle, sexual behaviour and the gels' safety and tolerability. At baseline and each follow-up visit (months 1, 2, 3, 6, 9 and 12), nurses collect anal specimens tested for 36 HPV types (linear array assay). HIV status is determined at baseline and 12 months. The primary outcome is incidence of type-specific anal HPV infection(s) undetected at baseline. Secondary outcomes are prevalence of type-specific anal HPV infection, safety, tolerability and adherence. We aim to recruit 380 participants to attain the study's objectives. Data will be analysed using intention-to-treat and per-protocol approaches with subgroup analyses by HIV status. ETHICS AND DISSEMINATION: Ethics approval was obtained by the Research Ethics Boards of McGill University, the McGill University Health Centre, Concordia University and Centre Hospitalier de l'Université de Montréal. Trial results will be disseminated through peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: NCT02354144.
Assuntos
Antivirais , Lubrificantes , Infecções por Papillomavirus , Administração Tópica , Adulto , Canal Anal/virologia , Antivirais/administração & dosagem , Antivirais/química , Antivirais/uso terapêutico , Homossexualidade Masculina , Humanos , Lubrificantes/administração & dosagem , Lubrificantes/química , Lubrificantes/uso terapêutico , Masculino , Infecções por Papillomavirus/tratamento farmacológico , Infecções por Papillomavirus/prevenção & controle , Infecções por Papillomavirus/transmissão , Ensaios Clínicos Controlados Aleatórios como Assunto , Minorias Sexuais e de GêneroRESUMO
BACKGROUND AND OBJECTIVES: Evaluating the efficacy of the fractional CO2 laser, promestriene, and vaginal lubricant to treat urinary symptoms in women with genitourinary syndrome of menopause. STUDY DESIGN/MATERIALS AND METHODS: We conducted a randomized clinical trial with 72 postmenopausal women aged 50 years or older. The participants were randomized to one intervention each in three treatment groups fractional CO2 laser, promestriene, and vaginal lubricant. Urinary symptoms were assessed prior to treatment and 2 weeks after treatment completion using validated questionnaires, the International Consultation on Incontinence Questionnaire (ICIQ-UI SF), and the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB). RESULTS: There was a significant reduction in the total ICIQ-UI SF score in the intragroup comparison (baseline vs. week 14) of the CO2 laser group (P = 0.004). This group also showed a statistically significant reduction in nocturia (1.33 ± 0.87 vs. 1.00 ± 0.76, respectively; P = 0.031). In the intergroup comparison after treatment, nocturia in the lubricant group had worsened compared with that of the other two groups (P = 0.002). Regarding the total ICIQ-OAB score, the results of the CO2 laser group were superior to those of the lubricant group in the intergroup comparison (7.76 ± 3.36, P = 0.020; analysis of variance P = 0.038). CONCLUSION: The results were significantly different between the intravaginal fractional CO2 laser and topical estrogen groups for treating urinary symptoms related to the genitourinary syndrome of menopause. Further controlled and randomized studies are needed. Lasers Surg. Med. © 2020 Wiley Periodicals, Inc.
Assuntos
Dióxido de Carbono , Pós-Menopausa , Estradiol/análogos & derivados , Feminino , Humanos , Lubrificantes/uso terapêutico , Resultado do Tratamento , VaginaRESUMO
Genitourinary syndrome of menopause is a condition describing the hypoestrogenic effects on the female genitals and lower urinary tract leading to symptoms such as vaginal dryness, vulvar and vaginal burning, dyspareunia and dysuria. Genitourinary syndrome of menopause is experienced by over half of postmenopausal women, and is even more pervasive in women with cancer. Due to treatments such as surgery, chemotherapy, radiation, and hormonal therapy, women may experience early menopause resulting in earlier and more severe symptoms. Understanding the scope of this issue in female breast and gynecologic cancer survivors and identifying treatment options for this complex patient population are paramount. Tailored patient treatments include nonhormonal therapies (vaginal moisturizers, lubricants, pelvic floor physical therapy, dilator therapy, counseling), systemic and local hormonal therapies. Consensus recommendations by medical societies and associated evidence are reviewed, with emphasis on safety and efficacy of local vaginal hormonal therapies, and management variations noted depending on cancer type and characteristics. With knowledge and understanding of the unmet need associated with under-recognition and under-treatment of genitourinary syndrome of menopause, providers caring for women with cancer are in a position to improve the quality of life of their patients by providing safe and effective treatments.
Assuntos
Neoplasias da Mama , Terapia de Reposição de Estrogênios/métodos , Doenças Urogenitais Femininas/terapia , Neoplasias dos Genitais Femininos , Menopausa , Administração Intravaginal , Anestésicos Locais/uso terapêutico , Sobreviventes de Câncer , Dispareunia/terapia , Disuria/terapia , Feminino , Humanos , Terapia a Laser , Lidocaína/uso terapêutico , Lipídeos/uso terapêutico , Lubrificantes/uso terapêutico , Seleção de Pacientes , Diafragma da Pelve , Modalidades de FisioterapiaRESUMO
Patients with breast cancer receiving antiestrogen therapy, specifically aromatase inhibitors, often suffer from vaginal dryness, itching, irritation, dyspareunia, and dysuria, collectively known as genitourinary syndrome of menopause (GSM). GSM can decrease quality of life and is undertreated by oncologists because of fear of cancer recurrence, specifically when considering treatment with vaginal estrogen therapy because of unknown levels of systemic absorption of estradiol. In this article, we review the available literature for treatment of GSM in patients with breast cancer and survivors, including nonhormonal, vaginal hormonal, and systemic hormonal therapy options. First-line treatment includes nonhormonal therapy with vaginal moisturizers, lubricants, and gels. Although initial studies showed significant improvement in symptoms, the US Food and Drug Administration recently issued a warning against CO2 laser therapy for treatment of GSM until additional studies are conducted. In severe or refractory GSM, after discussing risks and benefits of vaginal hormonal therapy, the low-dose 10-µg estradiol-releasing intravaginal tablet or lower-dose 4 µg estrogen vaginal insert and intravaginal dehydroepiandrosterone (prasterone) are options for treatment, because studies show minimal elevation in serum estradiol levels and significant improvement in symptoms. The decision to offer vaginal estrogen therapy must be individualized and made jointly with the patient and her oncologist.
Assuntos
Neoplasias da Mama , Sobreviventes de Câncer , Doenças Urogenitais Femininas/terapia , Menopausa , Inibidores da Aromatase/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Desidroepiandrosterona/uso terapêutico , Estrogênios/uso terapêutico , Feminino , Humanos , Terapia a Laser , Lubrificantes/uso terapêutico , Síndrome , Testosterona/uso terapêuticoAssuntos
Adjuvantes Imunológicos/uso terapêutico , Desidroepiandrosterona/uso terapêutico , Estrogênios/uso terapêutico , Doenças Urogenitais Femininas/tratamento farmacológico , Menopausa , Tamoxifeno/análogos & derivados , Administração Intravaginal , Atrofia/tratamento farmacológico , Feminino , Humanos , Lubrificantes/uso terapêutico , Tamoxifeno/uso terapêutico , Vagina/patologia , Vulva/patologiaRESUMO
Osteoarthritis (OA) is a chronic joint disease resulting from joint inflammation and damage. In this study, we employed a boundary lubricant known as a 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) liposome for loading of an anti-inflammatory drug d-glucosamine sulphate (GAS) to construct a treatment strategy allowing for sustained anti-inflammation and reduced damage. This kind of drug-loaded nanocarrier integrates the anti-inflammatory effect of the GAS and the lubrication ability of DSPC liposomes without the involvement of complex synthesis processes leading to easier popularization. Our experimental results indicated that the GAS-loaded DSPC liposomes could release GAS in a sustained manner while providing good lubrication in pure water (H2O) and phosphate buffered saline (PBS). Moreover, the GAS-loaded DSPC liposomes prepared at a 2 : 8 molar ratio in PBS exhibited a greater entrapment efficiency, lower GAS release rate and smaller friction coefficient as compared to those prepared in H2O. The superiority of the drug release and lubrication ability achieved with the GAS-loaded DSPC liposomes in PBS were elucidated on the basis of salt-induced enhancement in liposomal stability and hydration lubrication by the hydrated salt ions. Such GAS release accelerated the viability and proliferation of primary mouse chondrocytes while also providing the anti-inflammatory and chondroprotective potential for tumor necrosis factor (TNF-α) induced chondrocyte degeneration through the down-regulation of pro-inflammatory cytokines, pain related gene and catabolic proteases, as well as the up-regulation of anabolic components. We envision that the GAS-loaded DSPC liposomes could represent a promising new strategy for clinical treatment of OA in the future.
Assuntos
Glucosamina/administração & dosagem , Glucosamina/uso terapêutico , Lipossomos/química , Lubrificantes/administração & dosagem , Lubrificantes/uso terapêutico , Osteoartrite/tratamento farmacológico , Fosforilcolina/química , Animais , Condrócitos/efeitos dos fármacos , Condrócitos/metabolismo , Preparações de Ação Retardada , Regulação da Expressão Gênica/efeitos dos fármacos , Glucosamina/farmacologia , Lubrificantes/farmacologia , Camundongos , Fator de Necrose Tumoral alfa/metabolismo , Água/químicaRESUMO
OBJECTIVE: The objective of this study was to determine if there is a clinically meaningful variation in pain perception when using lidocaine gel versus plain lubricant prior to office-based diagnostic flexible cystoscopy. METHODS: This was a randomized, controlled, double-blind trial comparing lidocaine gel and water-based lubricant for the performance of diagnostic flexible cystoscopy. Women undergoing cystoscopy were randomized to either transurethral 2% lidocaine (Uro-Jet) or water-based lubricant prior to cystoscopy. Participants and physicians were blinded, and pain was assessed using an 11-point numeric rating scale (NRS). A priori sample size calculation indicated the need for 40 patients per group to achieve 90% power. Descriptive statistics and Student t test were utilized. RESULTS: The study included 116 patients, 61 in the lidocaine group and 55 in the plain lubricant group. Numeric rating scale in the lidocaine group (2.43 [SD, 1.95]) was significantly lower than that in the plain lubricant group (3.58 [SD, 2.73]) (P = 0.01). After controlling for age and ethnicity, separately as well as together, the procedural NRS scores were 1.37 points (P = 0.002), 0.97 points (P = 0.04), and 1.22 points (P = 0.01) lower in those receiving lidocaine. After the procedure, fewer patients in the lidocaine group (2/61 = 3.3%) requested pain medicine when compared with the plain lubricant group (11/55 = 20%) (P = 0.01). Although anticipated pain scored similarly between groups, actual pain compared with anticipated pain was significantly lower in the lidocaine group (P = 0.02). CONCLUSIONS: Pain perception during flexible cystoscopy decreased when using 2% transurethral lidocaine gel. The use of 2% lidocaine gel is suggested for the reduction of pain at the time of diagnostic flexible cystoscopy in women.
Assuntos
Anestésicos Locais , Cistoscopia/efeitos adversos , Lidocaína , Percepção da Dor/efeitos dos fármacos , Dor/etiologia , Dor/prevenção & controle , Adulto , Idoso , Analgésicos/uso terapêutico , Anestésicos Locais/farmacologia , Método Duplo-Cego , Feminino , Géis , Humanos , Lidocaína/farmacologia , Lubrificantes/uso terapêutico , Pessoa de Meia-Idade , Medição da DorRESUMO
Urogenital atrophy is more common than it would first appear and women do not always seek advice and guidance. Confusion still exists between systemic hormone replacement therapy (HRT) and local estrogen preparations but new treatment modalities have emerged that extend the range of options beyond lubricants, moisturisers and vaginal estrogen preparations.
Assuntos
Vagina/patologia , Vulva/patologia , Atrofia/diagnóstico , Atrofia/etiologia , Atrofia/terapia , Consenso , Terapia de Reposição de Estrogênios , Feminino , Humanos , Terapia a Laser , Lubrificantes/uso terapêutico , Moduladores Seletivos de Receptor Estrogênico/uso terapêutico , Sexualidade , Tamoxifeno/análogos & derivados , Tamoxifeno/uso terapêuticoRESUMO
Genitourinary syndrome of menopause (GSM) describes a collection of exam findings and bothersome symptoms associated with estrogen deficiency involving changes to the labia, introitus, clitoris, vagina, urethra, and bladder. Vulvovaginal atrophy is a component of GSM. GSM is a highly prevalent medical condition with adverse effects on the health and quality of life of midlife women. There are many effective treatment options, including nonhormonal lubricants and moisturizers, physical therapy, low-dose vaginal estrogen therapy, vaginal dehydroepiandrosterone, and oral ospemifene. Despite the availability of safe and effective therapies, GSM often remains unrecognized and untreated.